Diabetic Patients With Newly Diagnosed Chronic Myeloid Leukemia: TKI Choice and Early Adverse Events. A Real‐Life Survey Within the Italian Chronic Myeloid Leukemia Network
European Journal of Haematology · 2026
DOI: 10.1111/ejh.70268 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2026. Verfasst von S Russo und 42 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Section, AOU Policlinico G. Martino, University of Messina, Messina, Italy. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Diabetes Mellitus. Die Arbeit nennt 32 Literaturangaben.
Themen: Patientensicherheit
Abstract (Originalsprache)
Limited data are available regarding patients with newly diagnosed chronic myeloid leukemia (CML) and concomitant diabetes mellitus (DM). Hence, we retrospectively analyzed 2149 patients with newly diagnosed chronic phase (CP) CML to compare clinical characteristics, choice of frontline therapy, early adverse events, and molecular responses between patients with or without DM. Among this cohort of 2149 patients, 241 patients (11.2%) had DM at CML diagnosis. Diabetic patients were older (median age 69.6 vs. 58.2 years, p < 0.001), showed a higher Sokal/ELTS risk and had more comorbidities, resulting in more frequent polypharmacy. Imatinib was frequently selected as first‐line treatment in diabetic patients (71% vs. 53%, p < 0.001), whereas nilotinib was more common in nondiabetics (6.2% vs. 31.9%). Discontinuation by the 12th month occurred in 24.2% of diabetic patients versus 19.4% of nondiabetics ( p = 0.031), mainly for hematologic toxicity. Diabetic patients showed a lower incidence of major molecular response (MMR) at the 12th month (55.9% vs. 68.1%, p = 0.002). Among diabetic patients, a trend toward better molecular responses was observed in patients receiving metformin ( p = 0.068). In conclusion, DM represents a clinically meaningful comorbidity in newly diagnosed CML‐CP, and seems to define a subgroup with distinct features, influencing both treatment decisions and early outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Section, AOU Policlinico G. Martino, University of Messina, Messina, Italy.
- Hematology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
- Division of Hematology and BMT, Department of Medical Area, University of Udine, Udine, Italy.
- Hematology Department, San Bortolo Hospital, Vicenza, Italy.
- Hematology Division, Foundation IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Milan, Italy.
- Hematology Unit, University of Ferrara, Ferrara, Italy.
ORCID-Profile: I Capodanno, M Tiribelli, M C Miggiano, D Cattaneo, L Luciano, O Mulas, I Attolico, G Binotto, P Sportoletti, M Fazio, M Bocchia, C Fava, S Galimberti, I Vincelli, G Caocci, M Bonifacio, A Iurlo, A Allegra, G Saglio, G Specchia, M Breccia, F Stagno, R Latagliata
Zitieren
APA
Russo, S., Capodanno, I., Tiribelli, M., Miggiano, M. C., Cattaneo, D., Cavazzini, F., Leonetti Crescenzi, S., Scalzulli, E., Bernardelli, A., Luciano, L., Mulas, O., Loglisci, G., Elena, C., Morelli, G. L., Attolico, I., Binotto, G., Crisà, E., Sportoletti, P., Di Veroli, A., …, & Latagliata, R. (2026). Diabetic Patients With Newly Diagnosed Chronic Myeloid Leukemia: TKI Choice and Early Adverse Events. A Real‐Life Survey Within the Italian Chronic Myeloid Leukemia Network. European Journal of Haematology. https://doi.org/10.1111/ejh.70268
Vancouver
Russo S, Capodanno I, Tiribelli M, Miggiano MC, Cattaneo D, Cavazzini F, et al. Diabetic Patients With Newly Diagnosed Chronic Myeloid Leukemia: TKI Choice and Early Adverse Events. A Real‐Life Survey Within the Italian Chronic Myeloid Leukemia Network. European Journal of Haematology. 2026. doi:10.1111/ejh.70268
BibTeX
@article{Russo2026,
author = {Russo, S and Capodanno, I and Tiribelli, M and Miggiano, M C and Cattaneo, D and Cavazzini, F and Leonetti Crescenzi, S and Scalzulli, E and Bernardelli, A and Luciano, L and Mulas, O and Loglisci, G and Elena, C and Morelli, G L and Attolico, I and Binotto, G and Crisà, E and Sportoletti, P and Di Veroli, A and Scortechini, A R and Leporace, A P and Basile, M and Crugnola, M and Fazio, M and Murgano, P and Rapezzi, D and Luzi, D and Bocchia, M and Fava, C and Malato, A and Galimberti, S and Vincelli, I and Trawinska, M and Pizzuti, M and Caocci, G and Bonifacio, M and Iurlo, A and Allegra, A and Saglio, G and Specchia, G and Breccia, M and Stagno, F and Latagliata, R},
title = {Diabetic Patients With Newly Diagnosed Chronic Myeloid Leukemia: TKI Choice and Early Adverse Events. A Real‐Life Survey Within the Italian Chronic Myeloid Leukemia Network},
journal = {European Journal of Haematology},
year = {2026},
doi = {10.1111/ejh.70268}
}
EUVIMED